JP2015512435A - イソオキサゾリン化合物のための固形経口医薬組成物 - Google Patents
イソオキサゾリン化合物のための固形経口医薬組成物 Download PDFInfo
- Publication number
- JP2015512435A JP2015512435A JP2015503867A JP2015503867A JP2015512435A JP 2015512435 A JP2015512435 A JP 2015512435A JP 2015503867 A JP2015503867 A JP 2015503867A JP 2015503867 A JP2015503867 A JP 2015503867A JP 2015512435 A JP2015512435 A JP 2015512435A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solid oral
- oral pharmaceutical
- composition according
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 title claims abstract description 76
- 239000008203 oral pharmaceutical composition Substances 0.000 title claims abstract description 34
- 150000002547 isoxazolines Chemical class 0.000 title claims description 15
- -1 isoxazoline compound Chemical class 0.000 claims abstract description 117
- 241001465754 Metazoa Species 0.000 claims abstract description 32
- 239000002904 solvent Substances 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 26
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 22
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 20
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 20
- 244000045947 parasite Species 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 108010011485 Aspartame Proteins 0.000 claims description 11
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 11
- 239000000605 aspartame Substances 0.000 claims description 11
- 229960003438 aspartame Drugs 0.000 claims description 11
- 235000010357 aspartame Nutrition 0.000 claims description 11
- 229940113088 dimethylacetamide Drugs 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 10
- 239000008109 sodium starch glycolate Substances 0.000 claims description 10
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 10
- 239000003549 soybean oil Substances 0.000 claims description 10
- 235000012424 soybean oil Nutrition 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- YGLLICRFEVEWOZ-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate Chemical compound [Na+].[Na+].C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 YGLLICRFEVEWOZ-UHFFFAOYSA-L 0.000 claims description 8
- 125000004970 halomethyl group Chemical group 0.000 claims description 7
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 6
- 125000005767 propoxymethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])[#8]C([H])([H])* 0.000 claims description 6
- 206010061217 Infestation Diseases 0.000 claims description 5
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 4
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 4
- 125000004969 haloethyl group Chemical group 0.000 claims description 4
- 229960002418 ivermectin Drugs 0.000 claims description 4
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 claims description 4
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims description 4
- 229960004816 moxidectin Drugs 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims description 3
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 claims description 3
- 229920005555 halobutyl Polymers 0.000 claims description 3
- 125000004968 halobutyl group Chemical group 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims description 3
- 125000004673 propylcarbonyl group Chemical group 0.000 claims description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 3
- 150000002596 lactones Chemical class 0.000 claims description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000006300 thietan-3-yl group Chemical group [H]C1([H])SC([H])([H])C1([H])* 0.000 claims 2
- OXDDDHGGRFRLEE-UHFFFAOYSA-N 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide Chemical compound C12=CC=CC=C2C(C(=O)NCC(=O)NCC(F)(F)F)=CC=C1C(C1)=NOC1(C(F)(F)F)C1=CC(Cl)=CC(C(F)(F)F)=C1 OXDDDHGGRFRLEE-UHFFFAOYSA-N 0.000 claims 1
- 229960000982 afoxolaner Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 208000030852 Parasitic disease Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 47
- 241000282472 Canis lupus familiaris Species 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 241000238876 Acari Species 0.000 description 13
- 239000006186 oral dosage form Substances 0.000 description 11
- 230000001055 chewing effect Effects 0.000 description 10
- 244000078703 ectoparasite Species 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 8
- 239000007910 chewable tablet Substances 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 6
- 241000255925 Diptera Species 0.000 description 6
- 241000258242 Siphonaptera Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 0 CC(C1)=NOC1(*)C1=C*(**)C=CC=C1 Chemical compound CC(C1)=NOC1(*)C1=C*(**)C=CC=C1 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 235000015111 chews Nutrition 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- BPFUIWLQXNPZHI-UHFFFAOYSA-N 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-N-[(methoxyamino)methylidene]-2-methylbenzamide Chemical compound C1=C(C)C(C(=O)N\C=N/OC)=CC=C1C1=NOC(C(F)(F)F)(C=2C=C(Cl)C=C(Cl)C=2)C1 BPFUIWLQXNPZHI-UHFFFAOYSA-N 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 241001660203 Gasterophilus Species 0.000 description 3
- 241000920471 Lucilia caesar Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000244206 Nematoda Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241001414987 Strepsiptera Species 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FJBGLNSEMHYAPD-UHFFFAOYSA-N 5-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-3-methyl-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]thiophene-2-carboxamide Chemical compound S1C(C(=O)NCC(=O)NCC(F)(F)F)=C(C)C=C1C1=NOC(C(F)(F)F)(C=2C=C(Cl)C=C(Cl)C=2)C1 FJBGLNSEMHYAPD-UHFFFAOYSA-N 0.000 description 2
- 208000026803 Animal Parasitic disease Diseases 0.000 description 2
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 2
- 241000258924 Ctenocephalides felis Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- 241001481703 Rhipicephalus <genus> Species 0.000 description 2
- 240000000528 Ricinus communis Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 244000079386 endoparasite Species 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- MLBZKOGAMRTSKP-UHFFFAOYSA-N fluralaner Chemical compound C1=C(C(=O)NCC(=O)NCC(F)(F)F)C(C)=CC(C=2CC(ON=2)(C=2C=C(Cl)C=C(Cl)C=2)C(F)(F)F)=C1 MLBZKOGAMRTSKP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000002266 mite infestation Diseases 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- CDKJKDJRQFSWDX-UHFFFAOYSA-N 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]thiophene-2-carboxamide Chemical compound FC(CNC(=O)CNC(=O)C=1SC=CC=1C)(F)F CDKJKDJRQFSWDX-UHFFFAOYSA-N 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- IAZRALYVNARAFY-UHFFFAOYSA-N C(N)(=O)C1(C(=NOC1)C1=CC=CC=C1)NC(C1=CC=CC=C1)=O Chemical compound C(N)(=O)C1(C(=NOC1)C1=CC=CC=C1)NC(C1=CC=CC=C1)=O IAZRALYVNARAFY-UHFFFAOYSA-N 0.000 description 1
- SIZJHKRBAZCHTF-UHFFFAOYSA-N CCNC(c1ccncc1)=O Chemical compound CCNC(c1ccncc1)=O SIZJHKRBAZCHTF-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000252254 Catostomidae Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000258922 Ctenocephalides Species 0.000 description 1
- 241000490513 Ctenocephalides canis Species 0.000 description 1
- 241000426256 Cyanotis Species 0.000 description 1
- 239000005891 Cyromazine Substances 0.000 description 1
- 241001128004 Demodex Species 0.000 description 1
- 241001480824 Dermacentor Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 239000005893 Diflubenzuron Substances 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000322648 Felicola subrostratus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241001480796 Haemaphysalis Species 0.000 description 1
- 241000257224 Haematobia Species 0.000 description 1
- 241000875835 Haematopinus asini Species 0.000 description 1
- 241000268921 Heterodoxus spiniger Species 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000771999 Hippobosca Species 0.000 description 1
- 241000562421 Hydrotaea irritans Species 0.000 description 1
- 241000543830 Hypoderma bovis Species 0.000 description 1
- 241000257174 Hypoderma lineatum Species 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- 241000257162 Lucilia <blowfly> Species 0.000 description 1
- 241000257166 Lucilia cuprina Species 0.000 description 1
- 239000005912 Lufenuron Substances 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000257229 Musca <genus> Species 0.000 description 1
- 241000257159 Musca domestica Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- KBHCMKXZLFVXRD-UHFFFAOYSA-N NC(NCC(F)(F)F)=O Chemical compound NC(NCC(F)(F)F)=O KBHCMKXZLFVXRD-UHFFFAOYSA-N 0.000 description 1
- CUYKNJBYIJFRCU-UHFFFAOYSA-N Nc1cnccc1 Chemical compound Nc1cnccc1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N Nc1ncccc1 Chemical compound Nc1ncccc1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- 241000257191 Oestridae Species 0.000 description 1
- 241000543819 Oestrus ovis Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920002564 Polyethylene Glycol 3500 Polymers 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241001649229 Psoroptes Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000005927 Pyriproxyfen Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000509416 Sarcoptes Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 241000134399 Simulium sp. Species 0.000 description 1
- 241001494115 Stomoxys calcitrans Species 0.000 description 1
- 241000255626 Tabanus <genus> Species 0.000 description 1
- 239000005942 Triflumuron Substances 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- LVQDKIWDGQRHTE-UHFFFAOYSA-N cyromazine Chemical compound NC1=NC(N)=NC(NC2CC2)=N1 LVQDKIWDGQRHTE-UHFFFAOYSA-N 0.000 description 1
- 229950000775 cyromazine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 229960001673 diethyltoluamide Drugs 0.000 description 1
- QQQYTWIFVNKMRW-UHFFFAOYSA-N diflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C=C1 QQQYTWIFVNKMRW-UHFFFAOYSA-N 0.000 description 1
- 229940019503 diflubenzuron Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 229940093470 ethylene Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- YOWNVPAUWYHLQX-UHFFFAOYSA-N fluazuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C(OC=2C(=CC(=CN=2)C(F)(F)F)Cl)=C1 YOWNVPAUWYHLQX-UHFFFAOYSA-N 0.000 description 1
- 229950006719 fluazuron Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000020993 ground meat Nutrition 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960000521 lufenuron Drugs 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 229950003442 methoprene Drugs 0.000 description 1
- 229930002897 methoprene Natural products 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XAIPTRIXGHTTNT-UHFFFAOYSA-N triflumuron Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)NC(=O)C1=CC=CC=C1Cl XAIPTRIXGHTTNT-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Botany (AREA)
- Mechanical Engineering (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
または、R3およびR4は、一緒になって
R4は水素、エチル、メトキシメチル、ハロメトキシメチル、エトキシメチル、ハロエトキシメチル、プロポキシメチル、メチルカルボニル、エチルカルボニル、プロピルカルボニル、シクロプロピルカルボニル、メトキシカルボニル、メトキシメチルカルボニル、アミノカルボニル、エチルアミノカルボニルメチル、エチルアミノカルボニルエチル、ジメトキシエチル、プロピニルアミノカルボニルメチル、ハロエチルアミノカルボニルメチル、シアノメチルアミノカルボニルメチルまたはハロエチルアミノカルボニルエチルであるか;または、R3およびR4は、一緒になって
(式中、ZAは水素、ハロゲン、シアノ、ハロメチル(CF3)である)を形成する);またはそれらの塩もしくは溶媒和物と、固形担体と、2−ピロリドン、ジメチルアセトアミドまたはそれらの混合物から選択される溶媒と、を含む。
式中、Yは、メチル、臭素、Cl、F、CNまたはC(S)NH2であり、Qは上述のとおりである)。
4.4%w/w 式(I)の化合物、特にフルララネル
10.5%w/w 2−ピロリドン
25.0%w/w 微結晶セルロース
5.1%w/w デンプングリコール酸ナトリウム
15.0%w/w 香料
2.0%w/w ラウリル硫酸ナトリウム
2.5%w/w パモ酸ナトリウム
0.5%w/w アスパルテーム
0.5%w/w ステアリン酸マグネシウム
1.5%w/w グリセロール
17.25%w/w ダイズ油
15.75%w/w PEG8000
本処方物中のグリセロールの量は、0から12.0%、好ましくは0.5から10.0%の範囲であり得る。ダイズ油量は、5.0から25.0%、好ましくは10.0から22.0%の範囲であり得る。他の賦形剤の望ましい範囲は、デンプングリコール酸ナトリウム(2.0から15.0%)、香料(5から25%)、ラウリル硫酸ナトリウム(0.05から5.0%)、パモ酸ナトリウム(0.01から5.0%)、アスパルテーム(0.01から2.0%)およびステアリン酸マグネシウム(0.01から2.0%)を含む。
1.溶媒(例えば2−ピロリドン)中でイソオキサゾリン化合物(例えばフルララネルまたはアフォキソラネル)を溶解させ、溶液を生成させる。
ある実施形態において、本発明の生成物は、寄生性昆虫−、コナダニおよび/または蠕虫、特に寄生性昆虫および/またはコナダニ外寄生を駆除するための使用を対象とする。「寄生性昆虫−および/またはコナダニ外寄生を駆除する」という用語は、好ましくは数時間または数日内に昆虫および/またはコナダニまたは線虫寄生生物を死滅させることによって、動物におけるこのような寄生生物による外寄生を予防するか、減少させるかまたは排除することを指す。
2種類の活性成分を含有する直接圧縮錠に対する実施形態は、次のものを含む:
0.015%w/w イベルメクチン
2.5%w/w フルララネル
0.1%w/w クエン酸
0.5%w/w クレマフォアRH40
4.5%w/w 2−ピロリドン
50.0%w/w 微結晶セルロース
33.735%w/w コーンスターチ
8.0%w/w 香料
0.5% ステアリン酸マグネシウム
0.1%w/w アスパルテーム
0.05%w/w 赤色酸化鉄
[実施例2]
2種類の活性成分を含有する軟チュアブル錠に対する実施形態は、次のものを含む:
0.42%w/w モキシデクチン
1.67%w/w フルララネル
0.2%w/w クエン酸
4.0%w/w 2−ピロール
10.0%w/w 微結晶セルロース
3.0%w/w 香料
0.2%w/w アスパルテーム
4.0%w/w Klucel
30.51%w/w 粗びきダイズ
4.0%w/w プロピレングリコール
4.0%w/w Miglyol 812
8.0%w/w セチルアルコール
10.0%w/w クレマフォアRH40
20.0 %w/w デンプングリコール酸ナトリウム
[実施例3]
軟チュアブル錠に対するさらなる実施形態は、次のものを含む:
5.333%w/w フルララネル
9.0%w/w 2−ピロリドン
11.0%w/w 微結晶セルロース
5.0%w/w Pluronic 127
5.0%w/w ラウリル硫酸ナトリウム
10.0%w/w 香料
5.0%w/w デンプングリコール酸ナトリウム
16.667% 粗びきダイズ
2.0%w/w Labrasol
13.0%w/w Labrafac PG
18.0%w/w PEG3350
[実施例4]
7.25%w/w フルララネル
10.5%w/w 2−ピロリドン
22.75%w/w 微結晶セルロース
2.0% コロイド状二酸化シリコーン
3.5%w/w Lutrol Micro 127
3.5%w/w ラウリル硫酸ナトリウム
15.0%w/w 香料
0.5%w/w アスパルテーム
0.5%w/w ステアリン酸マグネシウム
2.0%w/w Labrasol
14.75%w/w ダイズ油
15.25%w/w PEG8000
[実施例5]
7.5%w/w フルララネル
7.0%w/w ジメチルアセトアミド
23.5%w/w 微結晶セルロース
15.0%w/w 香料
7.5%w/w デンプングリコール酸ナトリウム
3.5%w/w ラウリル硫酸ナトリウム
2.0%w/w パモ酸ナトリウム
0.5%w/w ステアリン酸マグネシウム
0.5%w/w アスパルテーム
7.0%w/w グリセロール
10.0%w/w ダイズ油
16.0%w/w PEG8000
[実施例6]
4.4%w/w フルララネル
10.5%w/w 2−ピロリドン
25.0%w/w 微結晶セルロース
15.0%w/w 香料
5.1%w/w デンプングリコール酸ナトリウム
3.5%w/w ラウリル硫酸ナトリウム
2.5%w/w パモ酸ナトリウム
0.5%w/w ステアリン酸マグネシウム
0.5%w/w アスパルテーム
3.0%w/w グリセロール
14.25%w/w ダイズ油
15.75%w/w PEG8000
[実施例7]
複数の処方物を軟チュアブル錠において処方した場合の、フルララネルのバイオアベイラビリティに対するそれらの影響について評価した。
イソオキサゾリン化合物のチュアブル製剤の経口投与後の薬物動態学的プロファイル
本研究の目的は、イヌにおける単回経口(PO)投与後の、2種類の異なるチュアブル製剤中の3種類の異なるイソオキサゾリン化合物の血漿薬物動態学的プロファイルを比較することである。
次の化合物を本発明に従い処方した。具体的には、イソオキサゾリン化合物を最初に溶媒、すなわち2−ピロリドン中で溶解させた。次に、固形担体、すなわち微結晶セルロース上にこの薬物溶液を吸着させ、これを表3に記載のような賦形剤を用いる仕様で記載されるとおり固形経口剤形に組み込んだ。比較実施例処方物ID番号13−009、13−011および13−013は、活性成分を予め溶解させ、固形担体へ吸着させることなく、本出願において全般的に記載されるように製造された固形物として組み込まれる活性薬物物質を含有する。
本試験化合物を1投与群あたり4匹、全部で24匹のビーグル犬に経口投与した。
本処方物(代替咀嚼剤)中で溶媒として2−ピロリドン(2−ピロール)を利用した場合、本処方物をより低用量で投与した場合でも(10mg/kg、対して対照の場合は25mg/kg)、対照咀嚼剤と比較して、同等またはより高い血漿レベルが観察された−図2参照。
Claims (29)
- 式(I)のイソオキサゾリン化合物:
(式中、R1=ハロゲン、CF3、OCF3、CNであり、n=0から3、好ましくは1、2または3の整数であり、R2=C1−C3−ハロアルキル、好ましくはCF3またはCF2Clであり、T=1以上のラジカルYにより置換されていてもよい5−または6員環であり、Y=メチル、ハロメチル、ハロゲン、CN、NO2、NH2−C=Sであるか、または2個の隣接するラジカルYが一緒に鎖、特に3または4員の鎖を形成し;Q=1以上のラジカルによって置換されていてもよい、X−NR3R4または5員N−ヘテロアリール環であり;X=CH2、CH(CH3)、CH(CN)、CO、CSであり、R3=水素、メチル、ハロエチル、ハロプロピル、ハロブチル、メトキシメチル、メトキシエチル、ハロメトキシメチル、エトキシメチル、ハロエトキシメチル、プロポキシメチル、エチルアミノカルボニルメチル、エチルアミノカルボニルエチル、ジメトキシエチル、プロピニルアミノカルボニルメチル、N−フェニル−N−メチル−アミノ、ハロエチルアミノカルボニルメチル、ハロエチルアミノカルボニルエチル、テトラヒドロフリル、メチルアミノカルボニルメチル、(N,N−ジメチルアミノ)−カルボニルメチル、プロピルアミノカルボニルメチル、シクロプロピルアミノカルボニルメチル、プロペニルアミノカルボニルメチル、ハロエチルアミノカルボニルシクロプロピル、
(式中、ZA=水素、ハロゲン、シアノ、ハロメチル(CF3)である)であり;R4=水素、エチル、メトキシメチル、ハロメトキシメチル、エトキシメチル、ハロエトキシメチル、プロポキシメチル、メチルカルボニル、エチルカルボニル、プロピルカルボニル、シクロプロピルカルボニル、メトキシカルボニル、メトキシメチルカルボニル、アミノカルボニル、エチルアミノカルボニルメチル、エチルアミノカルボニルエチル、ジメトキシエチル、プロピニルアミノカルボニルメチル、ハロエチルアミノカルボニルメチル、シアノメチルアミノカルボニルメチルまたはハロエチルアミノカルボニルエチルであるか;
または、R3およびR4は、一緒になって
および
からなる群から選択される置換基を形成する)
またはそれらの塩もしくは溶媒和物と;固形担体と、2−ピロリドン、ジメチルアセトアミドまたはそれらの混合物から選択される溶媒と、を含む、固形経口医薬組成物。 - 経口投与のための軟チュアブル獣医学用医薬組成物である、請求項1に記載の固形経口医薬組成物。
- 前記固形担体が微結晶セルロースである、請求項1または2に記載の固形経口医薬組成物。
- 前記溶媒が2−ピロリドンである、請求項1、2または3の何れかに記載の固形経口医薬組成物。
- 前記溶媒がジメチルアセトアミドである、請求項1、2または3の何れかに記載の固形経口医薬組成物。
- パモ酸または医薬的に許容可能なその塩をさらに含む、請求項1から5の何れかに記載の固形経口医薬組成物。
- 前記イソオキサゾリン化合物がフルララネルである、請求項1から6の何れかに記載の固形経口医薬組成物。
- 前記イソオキサゾリン化合物が、4−[5−(3,5−ジクロロフェニル)−4,5−ジヒドロ−5−(トリフルオロメチル)−3−イソオキサゾリル]−N−[(Z)−(メトキシイミノ)メチル]−2−メチル−ベンズアミドである、請求項1から7の何れかに記載の固形経口医薬組成物。
- 前記イソオキサゾリン化合物がアフォキソラネル(afoxolaner)である、請求項1から8の何れかに記載の固形経口医薬組成物。
- 前記イソオキサゾリン化合物が、5−[5−(3,5−ジクロロフェニル)−4,5−ジヒドロ−5−(トリフルオロメチル)−3−イソオキサゾリル]−3−メチル−N−[2−オキソ−2−[(2,2,2−トリフルオロエチル)アミノ]エチル]−2−チオフェンカルボキサミドである、請求項1から9の何れかに記載の固形経口医薬組成物。
- 前記イソオキサゾリン化合物が、4−[5−(3,5−ジクロロフェニル)−5−(トリフルオロメチル)−4H−イソオキサゾール−3−イル]−2−メチル−N−(チエタン−3−イル)ベンズアミドである、請求項1から10の何れかに記載の固形経口医薬組成物。
- さらなる医薬的に活性のある化合物を含む、請求項1から11の何れかに記載の固形経口医薬組成物。
- 前記さらなる医薬的に活性のある化合物が、イベルメクチン、ミルベマイシンおよびモキシデクチンの群から選択される大環状ラクトンである、請求項12に記載の固形経口医薬組成物。
- 式(I)のイソオキサゾリン化合物またはそれらの塩もしくは溶媒和物と、2−ピロリドンと、微結晶セルロースと、デンプングリコール酸ナトリウムと、ラウリル硫酸ナトリウムと、パモ酸ナトリウムと、ステアリン酸マグネシウムと、アスパルテームと、グリセロールと、ダイズ油と、ポリエチレングリコールと、を含む、請求項1、2、3、4、6、7、8、9、10、11、12または13に記載の固形経口医薬組成物。
- 式(I)のイソオキサゾリン化合物またはそれらの塩または溶媒和物と、ジメチルアセトアミドと、微結晶セルロースと、デンプングリコール酸ナトリウムと、ラウリル硫酸ナトリウムと、パモ酸ナトリウムと、ステアリン酸マグネシウムと、アスパルテームと、グリセロールと、ダイズ油と、ポリエチレングリコールと、を含む、請求項1、2、3、5、6、7、8、9、10、11、12または13に記載の固形経口医薬組成物。
- 前記溶媒中で請求項1、7、8、9、10または11で定められるようなイソオキサゾリン化合物を溶解させ、次いで得られた溶液を前記固形担体賦形剤上に吸着させることを含む、請求項1から15の何れかに記載の組成物を調製する方法。
- 前記固形担体賦形剤が微結晶セルロースである、請求項16に記載の方法。
- 前記溶媒が2−ピロリドンまたはジメチルアセトアミドである、請求項16または17に記載の方法。
- 前記溶媒が2−ピロリドンである、請求項18に記載の方法。
- 前記溶媒がジメチルアセトアミドである、請求項18に記載の方法。
- 動物において寄生生物の外寄生を制御する方法であって、治療的有効量の請求項1から15の何れかに記載の組成物を前記動物に投与することを含む、方法。
- 式(I)のイソオキサゾリン化合物またはそれらの塩もしくは溶媒和物および2−ピロリドンを含む、固形経口医薬組成物。
- 前記イソオキサゾリン化合物がフルララネルである、請求項22に記載の固形経口医薬組成物。
- 前記イソオキサゾリン化合物が、4−[5−(3,5−ジクロロフェニル)−4,5−ジヒドロ−5−(トリフルオロメチル)−3−イソオキサゾリル]−N−[(Z)−(メトキシイミノ)メチル]−2−メチル−ベンズアミドである、請求項22に記載の固形経口医薬組成物。
- 前記イソオキサゾリン化合物がアフォキソラネルである、請求項22に記載の固形経口医薬組成物。
- 前記イソオキサゾリン化合物が、5−[5−(3,5−ジクロロフェニル)−4,5−ジヒドロ−5−(トリフルオロメチル)−3−イソオキサゾリル]−3−メチル−N−[2−オキソ−2−[(2,2,2−トリフルオロエチル)アミノ]エチル]−2−チオフェンカルボキサミドである、請求項22に記載の固形経口医薬組成物。
- 前記イソオキサゾリン化合物が、4−[5−(3,5−ジクロロフェニル)−5−(トリフルオロメチル)−4H−イソオキサゾール−3−イル]−2−メチル−N−(チエタン−3−イル)ベンズアミドである、請求項22に記載の固形経口医薬組成物。
- 経口投与のための軟チュアブル獣医学用医薬組成物である、請求項22から27に記載の固形経口医薬組成物。
- 動物において寄生生物の外寄生を制御する方法であって、治療的有効量の請求項22から28の何れかに記載の組成物を前記動物に投与することを含む、方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12163198.0 | 2012-04-04 | ||
EP12163198 | 2012-04-04 | ||
US201361782028P | 2013-03-14 | 2013-03-14 | |
US61/782,028 | 2013-03-14 | ||
PCT/EP2013/056992 WO2013150055A1 (en) | 2012-04-04 | 2013-04-03 | Solid oral pharmaceutical compositions for isoxazoline compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015512435A true JP2015512435A (ja) | 2015-04-27 |
JP2015512435A5 JP2015512435A5 (ja) | 2016-05-26 |
JP6088637B2 JP6088637B2 (ja) | 2017-03-01 |
Family
ID=49300034
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015503867A Active JP6088637B2 (ja) | 2012-04-04 | 2013-04-03 | イソオキサゾリン化合物のための固形経口医薬組成物 |
JP2015503865A Active JP6148724B2 (ja) | 2012-04-04 | 2013-04-03 | ソフトなチュアブル医薬製品 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015503865A Active JP6148724B2 (ja) | 2012-04-04 | 2013-04-03 | ソフトなチュアブル医薬製品 |
Country Status (13)
Country | Link |
---|---|
US (15) | US9770440B2 (ja) |
EP (2) | EP2833867B2 (ja) |
JP (2) | JP6088637B2 (ja) |
KR (1) | KR102077874B1 (ja) |
CN (4) | CN108685894B (ja) |
AU (7) | AU2013245011B2 (ja) |
BR (3) | BR112014024833B1 (ja) |
CA (2) | CA2868381C (ja) |
ES (1) | ES2633611T5 (ja) |
NZ (1) | NZ631100A (ja) |
RU (3) | RU2765231C2 (ja) |
WO (2) | WO2013150052A1 (ja) |
ZA (2) | ZA201406968B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020503369A (ja) * | 2016-10-31 | 2020-01-30 | ザ・スクリップス・リサーチ・インスティテュート | 媒介体由来疾患伝染を予防する方法と組成物 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE112013000869T5 (de) | 2012-02-06 | 2014-10-16 | Merial Ltd. | Orale parasitizide Veterinärzusammensetzungen umfassend systemisch wirkende Wirkstoffe, Verfahren und Verwendun davon |
RU2765231C2 (ru) | 2012-04-04 | 2022-01-26 | Интервет Интернэшнл Б.В. | Мягкие жевательные фармацевтические продукты |
US9532946B2 (en) | 2012-11-20 | 2017-01-03 | Intervet Inc. | Manufacturing of semi-plastic pharmaceutical dosage units |
HUE046067T2 (hu) * | 2013-12-10 | 2020-02-28 | Intervet Int Bv | Izoxazolin vegyületek felhasználása paraziták ellen |
US10456358B2 (en) | 2013-12-20 | 2019-10-29 | Intervet Inc. | Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals |
HUE055444T2 (hu) * | 2013-12-20 | 2021-11-29 | Intervet Int Bv | Izoxazolinszármazákok felhasználása baromfiak arthropodafertõzéseinek kezelésére vagy megelõzésére |
US20170354593A1 (en) * | 2014-11-03 | 2017-12-14 | Zoetis Services Llc | Palatable chewable veterinary composition |
CN114681453A (zh) | 2014-12-22 | 2022-07-01 | 英特维特国际股份有限公司 | 异噁唑啉化合物用于治疗蠕形螨病的用途 |
UY36570A (es) | 2015-02-26 | 2016-10-31 | Merial Inc | Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas |
UY37137A (es) | 2016-02-24 | 2017-09-29 | Merial Inc | Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos |
WO2018039508A1 (en) | 2016-08-25 | 2018-03-01 | Merial, Inc. | Method for reducing unwanted effects in parasiticidal treatments |
AU2018307726C1 (en) | 2017-07-26 | 2023-03-30 | Tgx Soft Chew, Llc | Starch-free soft chew for veterinary applications |
MX2021002606A (es) * | 2018-09-05 | 2021-05-12 | Zoetis Services Llc | Formulaciones antiparasitarias agradables al paladar. |
AU2020316642A1 (en) * | 2019-07-22 | 2022-01-27 | Intervet International B.V. | Soft chewable veterinary dosage form |
WO2021122513A1 (en) * | 2019-12-16 | 2021-06-24 | Intervet International B.V. | Composition for lice control |
WO2022192623A1 (en) * | 2021-03-11 | 2022-09-15 | In The Bowl Animal Health, Inc. | Oral canine feed and methods for controlling flea infestations in a canine |
AU2022232440A1 (en) * | 2021-03-11 | 2023-09-21 | In The Bowl Animal Health, Inc. | Oral canine feed and methods for controlling tick infestations in a canine |
WO2022271937A2 (en) * | 2021-06-25 | 2022-12-29 | In The Bowl Animal Health, Inc. | Oral feline feed and methods for controlling flea infestations in a feline |
CN113476419A (zh) * | 2021-08-17 | 2021-10-08 | 江苏恒丰强生物技术有限公司 | 一种宠物用氟雷拉纳咀嚼片及其制备方法 |
CA3237113A1 (en) * | 2021-11-11 | 2023-05-19 | David Griffin | Soft chew |
WO2023198476A1 (en) | 2022-04-15 | 2023-10-19 | Krka, D.D., Novo Mesto | Soft chewable veterinary dosage form |
CN117122571A (zh) * | 2022-05-20 | 2023-11-28 | 天津瑞普生物技术股份有限公司 | 一种抗寄生虫感染的口服药物制剂及其制备方法和应用 |
FR3138315A1 (fr) | 2022-07-27 | 2024-02-02 | Virbac | Produit à usage vétérinaire et procédé pour sa fabrication |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060380A1 (en) * | 2000-02-16 | 2001-08-23 | Phoenix Scientific, Inc. | A parasiticidal formulation and a method of making this formulation |
JP2006502140A (ja) * | 2002-08-16 | 2006-01-19 | メリアル リミテッド | 非動物製品含有獣医製剤 |
WO2010070068A2 (en) * | 2008-12-19 | 2010-06-24 | Novartis Ag | Organic compounds |
JP2010531883A (ja) * | 2007-06-26 | 2010-09-30 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | ナフタレンイソキサゾリン無脊椎有害生物防除剤 |
JP2010531893A (ja) * | 2007-06-27 | 2010-09-30 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 動物有害生物の防除方法 |
JP2010536733A (ja) * | 2007-08-17 | 2010-12-02 | インターベツト・インターナシヨナル・ベー・ベー | イソオキサゾリン組成物および駆虫薬としてのそれらの使用 |
WO2013079407A1 (en) * | 2011-11-29 | 2013-06-06 | Novartis Ag | Aryl derivatives for controlling ectoparasites |
Family Cites Families (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB819681A (en) * | 1957-01-24 | 1959-09-09 | Wellcome Found | Improvements in and relating to quaternary ammonium compounds and the preparation thereof |
US3486186A (en) | 1967-05-08 | 1969-12-30 | Hollymatic Corp | Molding apparatus |
US3887964A (en) * | 1972-01-24 | 1975-06-10 | Formax Inc | Food patty molding machine |
US3952478A (en) | 1974-10-10 | 1976-04-27 | Formax, Inc. | Vacuum sheet applicator |
US4054967A (en) | 1975-10-20 | 1977-10-25 | Formax, Inc. | Food patty molding machine |
US4284652A (en) | 1977-01-24 | 1981-08-18 | The Quaker Oats Company | Matrix, product therewith, and process |
US4182003A (en) | 1978-02-28 | 1980-01-08 | Formax, Inc. | Food patty molding machine |
US4338702A (en) | 1979-03-29 | 1982-07-13 | Holly Harry H | Apparatus for making a ground food patty |
US4334339A (en) | 1980-05-12 | 1982-06-15 | Hollymatic Corporation | Mold device with movable compression insert |
US4356595A (en) | 1980-11-07 | 1982-11-02 | Formax, Inc. | Method and apparatus for molding food patties |
US4327076A (en) | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4343068A (en) | 1981-01-19 | 1982-08-10 | Holly James A | Method and apparatus for unidirectional formation of a plug-formed patty with cleanout feature |
US4372008A (en) | 1981-04-23 | 1983-02-08 | Formax, Inc. | Food patty molding machine with multi-orifice fill passage and stripper plate |
US4393085A (en) | 1981-08-13 | 1983-07-12 | General Foods Corporation | Enzyme digestion for a dog food of improved palatability |
IE53474B1 (en) | 1981-09-17 | 1988-11-23 | Warner Lambert Co | A chewable comestible product and process for its production |
CH657506A5 (de) | 1981-12-10 | 1986-09-15 | Hollymatic Ag | Portioniermaschine zum fuellen von hohlraeumen mit verformbarem material und verwendung derselben. |
US4535505A (en) | 1982-11-23 | 1985-08-20 | Holly Systems, Inc. | Method and apparatus for forming a patty to accommodate tissue fiber flow |
US4608731A (en) | 1983-01-11 | 1986-09-02 | Holly Systems, Inc. | Food patty with improved void structure, shape, and strength and method and apparatus for forming said patty |
US4609543A (en) | 1983-11-14 | 1986-09-02 | Nabisco Brands, Inc. | Soft homogeneous antacid tablet |
US4597135A (en) | 1984-02-21 | 1986-07-01 | Holly Systems, Inc. | Food patty forming method and apparatus employing two or more agitator bars |
DE3406497A1 (de) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
US4768941A (en) | 1986-06-16 | 1988-09-06 | Hollymatic Corporation | Food patty and machine and method for making thereof |
US4697308A (en) | 1986-10-29 | 1987-10-06 | Formax, Inc. | Patty molding mechanism for whole fiber food product |
DE3636882C1 (de) | 1986-10-30 | 1988-05-19 | Schreiber Berthold | Vorrichtung zur feinblasigen Einleitung eines Gases in eine Fluessigkeit |
US4714620A (en) | 1986-12-12 | 1987-12-22 | Warner-Lambert Company | Soft, sugarless aerated confectionery composition |
US4780931A (en) | 1987-02-13 | 1988-11-01 | Marlen Research Corporation | Feeding device for patty forming machine |
US4821376A (en) | 1988-06-02 | 1989-04-18 | Formax, Inc. | Seal-off for food patty molding machine with multi-orifice fill passage and stripper plate |
US4997671A (en) | 1988-09-09 | 1991-03-05 | Nabisco Brands, Inc. | Chewy dog snacks |
US4872241A (en) | 1988-10-31 | 1989-10-10 | Formax, Inc. | Patty molding mechanism for fibrous food product |
US4935243A (en) | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
US5021025A (en) | 1989-09-12 | 1991-06-04 | Wagner Richard C | Method and machine for making food patties |
US4975039A (en) | 1989-09-18 | 1990-12-04 | Dare Gary L | Food molding and portioning apparatus |
US4996743A (en) | 1990-01-29 | 1991-03-05 | Formax, Inc. | Mold plate drive linkage |
US5022888A (en) | 1990-05-03 | 1991-06-11 | Formax, Inc. | Co-forming apparatus for food patty molding machine |
US5262167A (en) | 1990-12-20 | 1993-11-16 | Basf Corporation | Edible, non-baked low moisture cholestyramine composition |
US5380535A (en) | 1991-05-28 | 1995-01-10 | Geyer; Robert P. | Chewable drug-delivery compositions and methods for preparing the same |
JP2575325B2 (ja) | 1991-06-18 | 1997-01-22 | サクマ製菓株式会社 | キャンディ |
US5439924A (en) | 1991-12-23 | 1995-08-08 | Virbac, Inc. | Systemic control of parasites |
TW376319B (en) | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
BR9507637A (pt) | 1994-05-20 | 1997-10-07 | Janssen Pharmaceutica Nv | Tabletes mastigáveis de flubendazol para animais de companhia |
US5637313A (en) | 1994-12-16 | 1997-06-10 | Watson Laboratories, Inc. | Chewable dosage forms |
GB9508443D0 (en) | 1995-04-26 | 1995-06-14 | Gilbertson & Page | Biscuit for working racing or sporting dogs |
AUPN290395A0 (en) | 1995-05-10 | 1995-06-01 | Virbac (Australia) Pty Limited | Canine anthelmintic preparation |
US5578336A (en) | 1995-06-07 | 1996-11-26 | Monte; Woodrow C. | Confection carrier for vitamins, enzymes, phytochemicals and ailmentary vegetable compositions and method of making |
SK74396A3 (en) | 1995-06-13 | 1997-04-09 | American Home Prod | Organoleptically acceptable oral pharmaceutical compositions |
US5606889A (en) | 1995-09-19 | 1997-03-04 | G & H Technology, Inc. | Reusable initiator for use in triggering high-load actuators |
DE19628776A1 (de) | 1996-07-17 | 1998-01-22 | Bayer Ag | Oral applizierbare Granulate von Hexahydropyrazinderivaten |
US5730650A (en) | 1996-08-29 | 1998-03-24 | Progressive Technology Of Wisconsin, Inc. | Food patty molding machine |
US5655436A (en) | 1996-08-29 | 1997-08-12 | Progressive Technology Of Manitowoc, Inc. | Food patty molding machine |
US6093427A (en) | 1997-09-03 | 2000-07-25 | T.F.H.Publications, Inc. | Vegetable-based dog chew |
US6110521A (en) | 1996-10-25 | 2000-08-29 | T.F.H. Publications, Inc. | Wheat and casein dog chew with modifiable texture |
US6086940A (en) | 1996-10-25 | 2000-07-11 | T.F.H. Publications, Inc. | High starch content dog chew |
US5827565A (en) | 1996-10-25 | 1998-10-27 | T.F.H. Publications, Inc. | Process for making an edible dog chew |
US5753255A (en) | 1997-02-11 | 1998-05-19 | Chavkin; Leonard | Chewable molded tablet containing medicinally active substances |
US6723358B1 (en) | 1998-03-23 | 2004-04-20 | General Mills, Inc. | Encapsulation of components into edible products |
US6093441A (en) | 1998-07-15 | 2000-07-25 | Tfh Publications, Inc. | Heat modifiable peanut dog chew |
US6270790B1 (en) | 1998-08-18 | 2001-08-07 | Mxneil-Ppc, Inc. | Soft, convex shaped chewable tablets having reduced friability |
US6387381B2 (en) | 1998-09-24 | 2002-05-14 | Ez-Med Company | Semi-moist oral delivery system |
US6060078A (en) | 1998-09-28 | 2000-05-09 | Sae Han Pharm Co., Ltd. | Chewable tablet and process for preparation thereof |
CA2349700A1 (en) * | 1998-11-12 | 2000-05-18 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
US6159516A (en) | 1999-01-08 | 2000-12-12 | Tfh Publication, Inc. | Method of molding edible starch |
GB9902073D0 (en) | 1999-01-29 | 1999-03-24 | Nestle Sa | Chewy confectionery product |
US6500463B1 (en) | 1999-10-01 | 2002-12-31 | General Mills, Inc. | Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
EP1103181A1 (de) * | 1999-11-25 | 2001-05-30 | Novartis AG | Kombination der N-Phenyl-N'-Benzoyl Harnstoff Derivaten und Avermectin für Parasiten Kontrolle. |
US6787342B2 (en) | 2000-02-16 | 2004-09-07 | Merial Limited | Paste formulations |
IT1317048B1 (it) | 2000-06-23 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie |
DE10031044A1 (de) | 2000-06-26 | 2002-01-03 | Bayer Ag | Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere |
PL207109B1 (pl) | 2001-01-31 | 2010-11-30 | Bayer Cropscience Ag | Kompozycja herbicyd-odtrutka i sposób zwalczania chwastów w uprawach roślin użytkowych |
EP1247456A3 (en) | 2001-02-28 | 2003-12-10 | Pfizer Products Inc. | Palatable pharmaceutical compositions for companion animals |
GB0108485D0 (en) | 2001-04-04 | 2001-05-23 | Pfizer Ltd | Combination therapy |
US20040234580A1 (en) | 2001-10-05 | 2004-11-25 | Huber Gordon R. | Animal feeds including actives and methods of using the same |
KR101030735B1 (ko) * | 2002-08-13 | 2011-04-26 | 인터벳 인터내셔널 비.브이. | 첨가제를 전달하는 조성물 및 전달 방법 |
US20040151759A1 (en) | 2002-08-16 | 2004-08-05 | Douglas Cleverly | Non-animal product containing veterinary formulations |
GB0219639D0 (en) | 2002-08-22 | 2002-10-02 | Prestwick Scient Capital Inc | Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders |
US20040234579A1 (en) | 2003-05-22 | 2004-11-25 | Mark D. Finke, Inc. | Dietary supplements and methods of preparing and administering dietary supplements |
TWI366442B (en) | 2003-07-30 | 2012-06-21 | Novartis Ag | Palatable ductile chewable veterinary composition |
AU2008201605B2 (en) | 2003-07-30 | 2010-04-29 | Novartis Ag | Palatable ductile chewable veterinary composition |
US6987111B2 (en) | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
WO2005016356A1 (en) | 2003-08-08 | 2005-02-24 | The Hartz Mountain Corporation | Improved anthelmintic formulations |
US7396819B2 (en) | 2003-08-08 | 2008-07-08 | Virbac Corporation | Anthelmintic formulations |
UA79571C2 (en) * | 2003-12-04 | 2007-06-25 | Basf Ag | Metod for the protection of seeds from soil pests comprising |
PE20051096A1 (es) | 2004-02-04 | 2006-01-23 | Novartis Ag | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida |
ES2526614T3 (es) | 2004-03-05 | 2015-01-13 | Nissan Chemical Industries, Ltd. | Compuesto de benzamida sustituida con isoxazolina y agente de control de organismos nocivos |
EP1734954A4 (en) | 2004-04-07 | 2007-05-30 | Intervet Int Bv | EFFECTIVE COMPOSITION OF A BENZIMIDAZOLE, AVERMECTIN AND PRAZIQUANTEL AND RELEVANT APPLICATION METHOD |
CA2562015A1 (en) † | 2004-04-09 | 2005-10-20 | Janssen Pharmaceutica Nv | Intermittent dosing regimens of apob secretion/mtp inhibitors for overweith and obese subjects |
US20050234119A1 (en) | 2004-04-16 | 2005-10-20 | Soll Mark D | Antiparasitical agents and methods for treating, preventing and controlling external parasites in animals |
DE102004034043A1 (de) * | 2004-07-13 | 2006-02-09 | Krka Tovarna Zdravil, D.D. | Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält |
US7348027B2 (en) * | 2005-04-08 | 2008-03-25 | Bayer Healthcare Llc | Taste masked veterinary formulation |
US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
MX2007014422A (es) * | 2005-05-20 | 2008-02-11 | Pfizer Ltd | Combinaciones sinergicas de farmacos atiinflamatorios con ligandos alfa-delta. |
AU2006285613B2 (en) | 2005-09-02 | 2011-11-17 | Nissan Chemical Corporation | Isoxazoline-substituted benzamide compound and harmful organism-controlling agent |
US7955632B2 (en) | 2005-12-07 | 2011-06-07 | Bayer B.V. | Process for manufacturing chewable dosage forms for drug delivery and products thereof |
US20070128251A1 (en) | 2005-12-07 | 2007-06-07 | Piedmont Pharmaceuticals, Inc. | Process for manufacturing chewable dosage forms for drug delivery and products thereof |
BRPI0620668A2 (pt) | 2005-12-14 | 2011-11-22 | Du Pont | composto da fórmula 1, composição que compreende composto, composição de controle de pragas invertebradas, composição de pulverização, composição de isca, dispositivo de armadilha, métodos de controle de pragas invertebradas, método de controle de baratas, formigas ou cupins e método de proteção de sementes contra pragas invertebradas |
TW200803740A (en) | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
TWI412322B (zh) * | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
EP1997813B1 (en) | 2006-03-10 | 2010-05-05 | Nissan Chemical Industries, Ltd. | Substituted isoxazoline compound and pest control agent |
BRPI0710403A2 (pt) | 2006-04-20 | 2011-08-09 | Du Pont | composto composição, composição de controle, de pulverização, de isca, dispositivo de armadilha, métodos de controle, métodos de proteção, semente tratada, composição de proteção |
TWI342532B (en) * | 2006-07-10 | 2011-05-21 | Himax Tech Inc | Method for generating a gamma table |
JP2008044880A (ja) * | 2006-08-15 | 2008-02-28 | Bayer Cropscience Ag | 殺虫性イソオキサゾリン類 |
AU2007293068C1 (en) | 2006-09-07 | 2013-09-19 | Boehringer Ingelheim Animal Health USA Inc. | Soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations |
CN101190223A (zh) * | 2006-11-29 | 2008-06-04 | 天津市润拓生物技术有限公司 | 一种犬猫用双羟萘酸噻嘧啶咀嚼片 |
US20090281059A1 (en) | 2007-02-21 | 2009-11-12 | Robert Falotico | Coating for a medical device having an anti-thrombotic conjugate |
JP5206993B2 (ja) | 2007-03-07 | 2013-06-12 | 日産化学工業株式会社 | イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤 |
KR20090130064A (ko) | 2007-04-10 | 2009-12-17 | 바이엘 크롭사이언스 아게 | 살충성 아릴 이속사졸린 유도체 |
JP2008260691A (ja) * | 2007-04-10 | 2008-10-30 | Bayer Cropscience Ag | 殺虫性アリールイソオキサゾリン誘導体 |
WO2008136791A1 (en) | 2007-05-03 | 2008-11-13 | Merial Limited | Compositions comprising c-13 alkoxyether macrolide compounds and phenylpyrazole compounds |
NZ580357A (en) * | 2007-05-07 | 2011-06-30 | Jurox Pty Ltd | Chewable gelatinised protein dosage form and process |
ME03373B (me) | 2007-05-15 | 2020-01-20 | Merial Inc | Ariloazol-2-il cijanoetilamino jedinjenja, postupci dobijanja i postupci njihove primene |
US20080293645A1 (en) | 2007-05-25 | 2008-11-27 | Schneider Lawrence F | Antiparasitic combination and method for treating domestic animals |
ES2445651T3 (es) | 2007-06-13 | 2014-03-04 | E. I. Du Pont De Nemours And Company | Insecticidas de isoxazolina |
EP2172448A4 (en) | 2007-06-29 | 2012-01-11 | Nissan Chemical Ind Ltd | SUBSTITUTED ISOXAZOLINE OR ENONOXINE COMPOUND AND PESTICIDES |
ITCL20070039A1 (it) | 2007-07-10 | 2009-01-11 | Michele Neri | Bombolo a pressione costante con tubo estrusore a proboscide e valvola dosatrice, agganciato ad una struttura su cui scorre, azionato da una fonte di pressione controllata, utilizzabile in particolare per la estrusione-lavorazione di tutte le paste: |
CN101801940B (zh) | 2007-09-10 | 2013-04-10 | 日产化学工业株式会社 | 取代异*唑啉化合物和有害生物防除剂 |
HUE043897T2 (hu) | 2007-09-25 | 2019-09-30 | Solubest Ltd | Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra |
JP5676262B2 (ja) | 2007-10-03 | 2015-02-25 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company | 有害無脊椎生物の防除用ナフタレンイソキサゾリン化合物 |
TWI411395B (zh) * | 2007-12-24 | 2013-10-11 | Syngenta Participations Ag | 殺蟲化合物 |
ES2582575T3 (es) | 2008-07-09 | 2016-09-13 | Nissan Chemical Industries, Ltd. | Procedimiento para la producción de compuesto de amida del ácido benzoico sustituido con isoxazolina |
CN102088857A (zh) * | 2008-07-09 | 2011-06-08 | 巴斯夫欧洲公司 | 包含异噁唑啉化合物的杀虫活性混合物ⅱ |
EP2306837B2 (en) * | 2008-07-09 | 2023-10-25 | Basf Se | Pesticidal active mixtures comprising isoxazoline compounds i |
JP2010026724A (ja) * | 2008-07-17 | 2010-02-04 | Fujitsu Ltd | Webページ提供装置、webページのランキング連動方法及びそのプログラム |
NZ590756A (en) | 2008-09-04 | 2013-01-25 | Syngenta Participations Ag | Insecticidal compounds |
US9820977B2 (en) * | 2008-10-03 | 2017-11-21 | Bayer Healthcare Llc | Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent |
SI3050874T1 (sl) | 2008-11-14 | 2019-04-30 | Merial Inc. | Enantiomerno obogatene ariloazol-2-il cianoetilamino paraziticidne spojine |
US8450357B2 (en) | 2008-11-19 | 2013-05-28 | Merial Limited | Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof |
MX2011005726A (es) | 2008-12-04 | 2011-07-29 | Merial Ltd | Derivados de avermectina y milbemicina dimericos. |
EP2379544B1 (en) | 2008-12-18 | 2013-10-16 | Novartis AG | Isoxazolines derivatives and their use as pesticide |
CN102325759A (zh) * | 2008-12-23 | 2012-01-18 | 巴斯夫欧洲公司 | 用于防治动物害虫的取代脒化合物 |
BRPI1007310A2 (pt) | 2009-01-22 | 2015-08-25 | Syngenta Participations Ag | Compostos inseticidas. |
US20120030841A1 (en) | 2009-04-01 | 2012-02-02 | Basf Se | Isoxazoline compounds for combating invertebrate pests |
AU2010100349B4 (en) * | 2009-04-15 | 2012-03-29 | Jurox Pty Ltd | Anthelmintic formulation |
US9040583B2 (en) | 2009-07-22 | 2015-05-26 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of disorders associated with G protein-coupled receptor 35 (GPR35) |
TWI487486B (zh) * | 2009-12-01 | 2015-06-11 | Syngenta Participations Ag | 以異唑啉衍生物為主之殺蟲化合物 |
AP3106A (en) | 2009-12-17 | 2015-01-31 | Merial Ltd | Antiparisitic dihydroazole compounds and compositions comprising same |
JP2013518084A (ja) | 2010-02-01 | 2013-05-20 | ビーエーエスエフ ソシエタス・ヨーロピア | 有害動物を駆除するための置換されたケトン性イソオキサゾリン化合物および誘導体 |
US20130085064A1 (en) | 2010-02-25 | 2013-04-04 | Syngenta Crop Protection Llc | Pesticidal mixtures containing isoxazoline derivatives and insecticide or nematoicidal biological agent |
EP2556060A1 (en) | 2010-04-08 | 2013-02-13 | Ah Usa 42 Llc | Substituted 3,5- diphenyl-isoxazoline derivatives as insecticides and acaricides |
CN101919857B (zh) * | 2010-05-05 | 2012-05-30 | 四川宝盛康药业有限公司 | 一种复方阿苯达唑咀嚼片及其应用和制备方法 |
MY156670A (en) | 2010-05-27 | 2016-03-15 | Du Pont | Crystalline form of 4-[5-[3-chloro-5-(trifluoromethly)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl) amino]ethyl]-1-naphthalenecarboxamide |
EP2579723A2 (en) | 2010-06-09 | 2013-04-17 | Syngenta Participations AG | Pesticidal mixtures comprising isoxazoline derivatives |
WO2011154434A2 (en) | 2010-06-09 | 2011-12-15 | Syngenta Participations Ag | Pesticidal mixtures including isoxazoline derivatives |
EP2579724A2 (en) | 2010-06-09 | 2013-04-17 | Syngenta Participations AG | Pesticidal mixtures including isoxazoline derivatives |
UY33403A (es) | 2010-06-17 | 2011-12-30 | Novartis Ag | Compuestos orgánicos con novedosas isoxazolinas, sus n-óxidos, s-óxidos y sales |
DK178277B1 (da) | 2010-06-18 | 2015-10-26 | Novartis Tiergesundheit Ag | Diaryloxazolinforbindelser til bekæmpelse af fiskelus |
CA2804147A1 (en) | 2010-06-30 | 2012-01-05 | Upsher-Smith Laboratories, Inc. | Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid |
WO2012007426A1 (en) | 2010-07-13 | 2012-01-19 | Basf Se | Azoline substituted isoxazoline benzamide compounds for combating animal pests |
JP2012046486A (ja) * | 2010-07-30 | 2012-03-08 | Sumitomo Chemical Co Ltd | 動物外部寄生虫防除剤 |
KR101508862B1 (ko) | 2010-08-05 | 2015-04-07 | 조에티스 엘엘씨 | 구충제로서 이속사졸린 유도체 |
WO2012038851A1 (en) | 2010-09-24 | 2012-03-29 | Pfizer Inc. | Isoxazoline oximes as antiparasitic agents |
US9744127B2 (en) | 2010-10-12 | 2017-08-29 | Bayer Intellectual Property Gmbh | Non-starch based soft chewables |
RU2749733C2 (ru) * | 2010-12-27 | 2021-06-16 | Интервет Интернэшнл Б.В. | Состав изоксазолина для местного и наружного применения |
DK2755473T3 (en) | 2011-09-12 | 2019-03-11 | Merial Inc | PARACITICIDE COMPOSITIONS CONTAINING AN ISOXAZOLINE ACTIVE SUBSTANCE, PROCEDURES AND APPLICATIONS THEREOF |
DE112013000869T5 (de) * | 2012-02-06 | 2014-10-16 | Merial Ltd. | Orale parasitizide Veterinärzusammensetzungen umfassend systemisch wirkende Wirkstoffe, Verfahren und Verwendun davon |
RU2765231C2 (ru) * | 2012-04-04 | 2022-01-26 | Интервет Интернэшнл Б.В. | Мягкие жевательные фармацевтические продукты |
US9532946B2 (en) | 2012-11-20 | 2017-01-03 | Intervet Inc. | Manufacturing of semi-plastic pharmaceutical dosage units |
-
2013
- 2013-04-03 RU RU2017133665A patent/RU2765231C2/ru active
- 2013-04-03 EP EP13717212.8A patent/EP2833867B2/en active Active
- 2013-04-03 RU RU2014144001A patent/RU2632965C2/ru active
- 2013-04-03 BR BR112014024833-8A patent/BR112014024833B1/pt active IP Right Grant
- 2013-04-03 EP EP13715654.3A patent/EP2833866B1/en active Active
- 2013-04-03 RU RU2014144360A patent/RU2646483C2/ru active
- 2013-04-03 JP JP2015503867A patent/JP6088637B2/ja active Active
- 2013-04-03 CN CN201810385736.3A patent/CN108685894B/zh active Active
- 2013-04-03 NZ NZ631100A patent/NZ631100A/en unknown
- 2013-04-03 BR BR112014024832-0A patent/BR112014024832B1/pt active IP Right Grant
- 2013-04-03 CN CN201380017735.9A patent/CN104203214B/zh active Active
- 2013-04-03 AU AU2013245011A patent/AU2013245011B2/en active Active
- 2013-04-03 CN CN201811130374.XA patent/CN109010296A/zh active Pending
- 2013-04-03 JP JP2015503865A patent/JP6148724B2/ja active Active
- 2013-04-03 AU AU2013245008A patent/AU2013245008B2/en active Active
- 2013-04-03 ES ES13717212T patent/ES2633611T5/es active Active
- 2013-04-03 CN CN201380029186.7A patent/CN104334159A/zh active Pending
- 2013-04-03 US US14/390,052 patent/US9770440B2/en active Active
- 2013-04-03 BR BR122022008957-7A patent/BR122022008957B1/pt active IP Right Grant
- 2013-04-03 CA CA2868381A patent/CA2868381C/en active Active
- 2013-04-03 CA CA2869242A patent/CA2869242C/en active Active
- 2013-04-03 WO PCT/EP2013/056987 patent/WO2013150052A1/en active Application Filing
- 2013-04-03 KR KR1020147027827A patent/KR102077874B1/ko active IP Right Grant
- 2013-04-03 WO PCT/EP2013/056992 patent/WO2013150055A1/en active Application Filing
- 2013-04-03 US US14/390,040 patent/US20150057321A1/en not_active Abandoned
-
2014
- 2014-09-23 ZA ZA2014/06968A patent/ZA201406968B/en unknown
-
2016
- 2016-11-29 ZA ZA2016/08614A patent/ZA201608614B/en unknown
- 2016-12-21 US US15/386,100 patent/US20170100377A1/en not_active Abandoned
- 2016-12-23 US US15/390,244 patent/US20170105972A1/en not_active Abandoned
-
2017
- 2017-02-15 US US15/433,840 patent/US20170172986A1/en not_active Abandoned
- 2017-02-15 US US15/433,901 patent/US20170172918A1/en not_active Abandoned
- 2017-06-05 US US15/613,848 patent/US20170266165A1/en not_active Abandoned
- 2017-06-22 AU AU2017204246A patent/AU2017204246A1/en not_active Abandoned
- 2017-06-27 US US15/634,924 patent/US11337917B2/en active Active
- 2017-11-27 AU AU2017268487A patent/AU2017268487A1/en not_active Abandoned
-
2018
- 2018-05-17 US US15/982,879 patent/US20190117564A1/en not_active Abandoned
- 2018-05-17 US US15/982,904 patent/US20190117565A1/en not_active Abandoned
-
2019
- 2019-03-08 US US16/296,490 patent/US11285101B2/en active Active
- 2019-07-11 US US16/508,758 patent/US20200000718A1/en not_active Abandoned
- 2019-08-07 AU AU2019213359A patent/AU2019213359A1/en not_active Abandoned
- 2019-10-09 AU AU2019246812A patent/AU2019246812B2/en active Active
-
2021
- 2021-03-02 US US17/189,939 patent/US11712416B2/en active Active
- 2021-11-11 AU AU2021266292A patent/AU2021266292A1/en active Pending
-
2022
- 2022-01-25 US US17/648,841 patent/US20220142984A1/en active Pending
-
2023
- 2023-06-15 US US18/335,415 patent/US20230320981A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060380A1 (en) * | 2000-02-16 | 2001-08-23 | Phoenix Scientific, Inc. | A parasiticidal formulation and a method of making this formulation |
JP2006502140A (ja) * | 2002-08-16 | 2006-01-19 | メリアル リミテッド | 非動物製品含有獣医製剤 |
JP2010531883A (ja) * | 2007-06-26 | 2010-09-30 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | ナフタレンイソキサゾリン無脊椎有害生物防除剤 |
JP2010531893A (ja) * | 2007-06-27 | 2010-09-30 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 動物有害生物の防除方法 |
JP2010536733A (ja) * | 2007-08-17 | 2010-12-02 | インターベツト・インターナシヨナル・ベー・ベー | イソオキサゾリン組成物および駆虫薬としてのそれらの使用 |
WO2010070068A2 (en) * | 2008-12-19 | 2010-06-24 | Novartis Ag | Organic compounds |
WO2013079407A1 (en) * | 2011-11-29 | 2013-06-06 | Novartis Ag | Aryl derivatives for controlling ectoparasites |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020503369A (ja) * | 2016-10-31 | 2020-01-30 | ザ・スクリップス・リサーチ・インスティテュート | 媒介体由来疾患伝染を予防する方法と組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6088637B2 (ja) | イソオキサゾリン化合物のための固形経口医薬組成物 | |
JP6514754B2 (ja) | 経表面局所イソオキサゾリン製剤 | |
JP6539384B2 (ja) | グリコフロールを含む経表面局所イソオキサゾリン製剤 | |
RU2772279C2 (ru) | Твердые фармацевтические композиции для перорального введения на основе изоксазолиновых соединений | |
KR102193090B1 (ko) | 국소 적용 이속사졸린 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160331 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160331 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170203 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6088637 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |